TY - JOUR
T1 - The impact of the fungal priority pathogens list on medical mycology: A perspective from Northern Europe
AU - Arendrup, Maiken Cavling
AU - Armstrong-James, Darius
AU - Borman, Andrew M.
AU - Denning, David
AU - Fisher, Matthew C.
AU - Gorton, Rebecca
AU - Maertens, Johan
AU - Martin-Loeches, Ignacio
AU - Mehra, Varun
AU - Mercier, Toine
AU - Price, Jessica
AU - Richardson, Riina
AU - Wake, Rachel
AU - Andrews, Natalie
AU - White, P Lewis
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Fungal diseases represent a considerable global health concern, affecting over one billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programmes should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate healthcare professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organised a workshop with key experts from Northern Europe to discuss the impact the FPPL will have on regional clinical practice.
AB - Fungal diseases represent a considerable global health concern, affecting over one billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programmes should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate healthcare professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organised a workshop with key experts from Northern Europe to discuss the impact the FPPL will have on regional clinical practice.
KW - Fungal priority pathogens
KW - medical mycology
KW - World Health Organization
KW - resistance
U2 - 10.1093/ofid/ofae372
DO - 10.1093/ofid/ofae372
M3 - Article
SN - 2328-8957
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
M1 - ofae372
ER -